Ma Xin Zhang Wenhong led!Shanghai big sample data research revealed the progress rate of Omikon's severe illness

19.06.2022

Number of this text: 1294, reading time for about 2 minutes

Introduction: The most important thing for this study is to tell us that we should identify patients with mild illness, find out the fragile crowd, and implement accurate prevention and control of the fragile people to reduce the mortality of the fragile people and reduce the damage of Omikon to lower Essence

Author | First Financial Money Children's Heart

Evaluating the severe spread of the new crown Omikon virus in different populations will help make a judgment of the burden on the disease, which is essential for future epidemic prevention strategies.

On June 18, China CDC Weekly, a China Centers for Prevention and Control Center, published a research on a large sample data led by Professor Zhang Wenhong and Professor Ma Xin, a large sample data of Huashan Hospital affiliated to Shanghai Fudan University. The severe rate of patients is zero.

Specifically, this multi -center clinical follow -up study was incorporated into 3,3816 early non -intensive Omiro infections from March 22 to May 3 this year. In the end %(22/33816), the severe rate of the high risk group was 0.238%(22/9260), and the severe severe group severe group was 0%(0/24556).

It should be emphasized that all infected people incorporated into this study are new crown patients who have no basic diseases or have a basic disease but are in a stable period. Initially, the researchers divided the patient into a severe/dangerous high -risk factor group (9260) and the non -high -risk factor group (24,556). The high -risk group is defined as: older than 60 years; cardiovascular and cerebrovascular diseases (including hypertension), chronic diseases in the lungs, diabetes, chronic liver disease, kidney disease, tumor and other basic diseases; immune function defects.

Studies have also found that compared with patients who have not progressed as severe infections, the average age of infected people with severe illnesses (75.8 years old VS 60) and the proportion of vaccine (54.5% vs 24.2%).

"The severity rate of this study can only represent the infection of Omikon who is relatively healthy or generally generally. Patients can still progress to severe illnesses. Severeness is mainly concentrated in patients with many types of basic diseases, and there are many types of basic diseases. "

This means that even in non -severe infection, there are still fragile people who are easily attacked by Omikon. "The most important thing for such a study is to tell us that we should identify patients with mild illness, find out the fragile crowd, and implement accurate prevention and control of the fragile crowd to reduce the mortality of the fragile people and reduce the damage of Omikon to lower. "The research team in this article said.

Since the outbreak of the Omikon out of Shanghai Omikon in February 2022, as of June 17, 5,8101 local diagnosis cases in Shanghai, 591499 cases of non -symptoms (unlattered). Since the non -severe Omikon infected people account for more than 95%of the total infected population, by giving this group of basic medical support to a certain degree of basic medical support, the overall medical resource expenditure in the population is expected to avoid the medical resources during the epidemic peak period. Squeeze.

In addition, the study also comprehensively described the clinical characteristics of non -intensive Omeckor infected by non -stable basic diseases for the first time. Research data shows that among patients with mild symptoms, the most common clinical manifestations are cough, sputum, fatigue, and fever. The median time with a continuous symptom is 7 days; the average nucleic acid turns to 6 days. Symptoms will extend the time of nucleic acid to the overcast time, and the vaccine that has been inoculated for two doses and above will shorten the nucleic acid to the overcast time.

It is worth noting that although Omikon is relatively unable to plant or damage the lungs compared to Delta's mutant strains, there may be fewer cases that may lead to risk pneumonia and respiratory distress. However, in this study, researchers found that some of the first -serious Omikon patients may still suffer from pneumonia, including young people.

Research data show that 11.1%of new coronary pneumonia patients are less than 40 years old, the youngest is 22 years old, 72.7%does not have basic diseases, and only one person has not vaccinated vaccines. "Although young, vaccinated, and no potential diseases can be used as a protection factor for developing as severe diseases, these factors cannot provide 100%pneumonia protection." Research authors wrote.

"This study provided valuable data for people to understand Omikon." Professor Cao Bin, a China -Japan Friendship Hospital who did not participate in this study, told the first financial reporter.

- END -